SITE005-0317

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-03-09

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-21 (study day 55); relationship: not assessed

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-29 (study day 186); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-22 (study day 209); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-05-05 (study day 405); relationship: not assessed

severe assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-05-29 (study day 429); relationship: not assessed

Data queries

No data queries.